Prosecuting Part D: Beware of Free Goods, Value Adds
This article was originally published in RPM Report
Managed care contracts are entering a period of unprecedented scrutiny. With year one of the Medicare Part D program drawing to a close, prosecutors are preparing to take the gloves off. What will they be looking for?
You may also be interested in...
Off-label use of prescription drugs is worth billions of dollars to manufacturers, but no one likes to talk about it. Defensiveness is understandable, with scores of companies under investigations for allegedly promoting those uses illegally. The truth is that no one is very happy about the current state of off-label medication use, but calls for change are contradictory and tough to resolve.
The pay-for-performance (P4P) model, which allows hospitals and physicians to be compensated with higher payer reimbursement for providing documented quality care, is becoming a standard practice with a growing number of private insurers, and the federal government wants to use a P4P system for Medicare.
Medicare beneficiaries stuck with their Part D plans heading into 2007. That gives insurers more leverage in price negotiations with big pharma. It also means Part D may be more likely to stick around despite critics in the Democratic Congress.